

AXIRON NET SALES, QUARTER TO 30 JUNE 2015

Acrux (ASX: ACR) today confirmed that Eli Lilly reported global Axiron net sales of USD\$32.4 million in its financial results for the quarter ended 30 June 2015.

Based on IMS data for the United States:

- Market share for both new prescriptions and total prescriptions for the quarter was consistent with recent prior quarters.
- The total number of prescriptions for Axiron in the quarter ended 30 June, 2015 declined by 1% compared to the March 2015 quarter.

Axiron net sales for Acrux's financial year ended 30 June 2015 and the prior year are shown in the following table:

Q3 2013	Q4 2013	Q1 2014	Q2 2014	Total FY 2014
US\$40.6m	US\$53.9m	US\$39.5m	US\$47.1m	US\$181.1m
Q3 2014	Q4 2014	Q1 2015	Q2 2015	Total FY 2015
US\$36.3m	US\$47.6m	US\$39.1m	US\$32.4m	US\$155.4m

For the fiscal year ending 30 June 2015, Acrux earned royalties from Axiron of US\$19.2 million, compared to US\$22.3 million in the previous year.



Contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including AXIRON[®], Evamist[®] and Recuvyra[™], is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.

For further information on Acrux, visit www.acrux.com.au

